Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses
Dona, A. A.; Caserta, E.; Singer, M.; Tandoh, T.; Nigam, L.; Winchester, J.; Chowdhury, A.; Zhu, Y.; Murtadha, M.; Pozhitkov, A.; Sanchez, J.; Vahed, H.; Coffey, M.; Marcucci, G.; Krishnan, A.; Nuovo, G.; Sborov, D.; Hofmeister, C. C.; Pichiorri, F.
Show abstract
Reovirus is an oncolytic virus with natural tropism for cancer cells. We previously showed that reovirus intravenous administration in myeloma patients was safe, but disease control associated with viral replication in the cancer cells was not observed. Here we show that ex vivo proteasome inhibitors (PIs) potentiate reovirus replication in circulating classical monocytes, increasing viral delivery to myeloma cells. We found that the anti-viral signals in monocytes primarily rely on the NF-kB activation and that this effect is impaired by the addition of PIs. Conversely, PIs improved reovirus-induced monocyte and T cell activation against cancer cells. Based on these preclinical data, we conducted a phase 1b trial of the reovirus Pelareorep together with the PI carfilzomib in 13 heavily pretreated bortezomib-resistant MM patients. Objective responses associated with reovirus active replication in MM cells, T cell activation and monocytic expansion were noted in 70% of patients.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments 95%
- IL-7-mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models 94%
- Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy 94%
Similar papers in this journal
- Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting 95%
- Low-affinity CAR T cells exhibit reduced trogocytosis, preventing fratricide and antigen-negative tumor escape while preserving anti-tumor activity 94%
- Establishment and Characterization of a CCND1-Rearranged Non-Mantle Cell Lymphoma Cell Line and Patient-Derived Xenograft Model 94%
Similar papers in this journal
- The Sec61 translocon is a therapeutic vulnerability in Multiple Myeloma 95%
- Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profile 94%
- Nirmatrelvir treatment blunts the development of antiviral adaptive immune responses in SARS-CoV-2 infected mice 92%
Similar papers in this journal
- Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer 95%
- Endoglin, a novel biomarker and therapeutical target to prevent malignant peripheral nerve sheath tumor growth and metastasis 94%
- Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML 93%
Similar papers in this journal
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 94%
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers 94%
- Accelerated single cell seeding in relapsed multiple myeloma 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.